Norton Oliveira, Senior Vice President, Head of Latin America, Alnylam Pharmaceuticals
Norton Oliveira is the Senior Vice President, Head of LATAM at Alnylam Pharmaceuticals, the leading company in the translation of RNA interference (RNAi) into a new class of innovative medicines. Based on Nobel Prize-winning science, RNAi therapeutics represent a clinically validated approach for the treatment of diseases with high unmet need. Founded in 2002 and Headquartered in Cambridge/MA, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including four investigational medicines in late-stage development and one product commercialized in the US, European Union, Japan and Canada, with plans to expand to markets around the world.
In this role, Norton is responsible to lead Alnylam geographic expansion to Latin America, defining the strategic direction and activity of all Alnylam’s operations the region, including the definition of the go-to-market strategy across multiple products and therapeutic areas, with an initial focus on building capabilities in Brazil.
Norton has 23 years of biopharma industry experience working in companies like Gilead Sciences, MSD, Shire and Janssen, with extensive international experience and a track record of building bridges between the private and public sectors, advancing important Public Health policies in a broad range of countries.
Norton is a current member of the Innovation Council of the City of Coral Gables/FL, supporting the municipality goal to transform Coral Gables in a Smart city and an innovation hub for the Americas.
Norton holds an MBA from ESPM – Sao Paulo and a bachelor’s degree in Business from USP – University of Sao Paulo, top tier universities in Brazil.